Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tracking Agouron

Executive Summary

Despite growing sales of {Viracept}, Agouron's stock is in the doldrums. It needs a follow-on product, but doesn't have any great near-term prospects of its own and can't spend the research funds necessary to develop earlier ones without hurting earnings. Agouron is therefore turning to licensing later-stage drugs and simultaneously remaking its share structure with tracking stocks. Its idea is to sequester R&D spending into a separately traded cancer company and thereby spare the income statement of Agouron-Viracept.
Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV000997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel